These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22488107)

  • 1. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.
    Kutlar A; Ataga KI; McMahon L; Howard J; Galacteros F; Hagar W; Vichinsky E; Cheung AT; Matsui N; Embury SH
    Am J Hematol; 2012 May; 87(5):536-9. PubMed ID: 22488107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular adhesion and the endothelium: P-selectin.
    Kutlar A; Embury SH
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):323-39. PubMed ID: 24589269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression.
    Klings ES; Anton Bland D; Rosenman D; Princeton S; Odhiambo A; Li G; Bernard SA; Steinberg MH; Farber HW
    Am J Hematol; 2008 Jul; 83(7):547-53. PubMed ID: 18383329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal sublingual microcirculation during painful crisis in sickle cell disease.
    van Beers EJ; Goedhart PT; Unger M; Biemond BJ; Ince C
    Microvasc Res; 2008 May; 76(1):57-60. PubMed ID: 18423765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational selectin-targeted therapy of sickle cell disease.
    Okpala I
    Expert Opin Investig Drugs; 2015 Feb; 24(2):229-38. PubMed ID: 25243412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Big strokes in small persons.
    Adams RJ
    Arch Neurol; 2007 Nov; 64(11):1567-74. PubMed ID: 17998439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
    Conran N; Fattori A; Saad ST; Costa FF
    Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo.
    Embury SH; Matsui NM; Ramanujam S; Mayadas TN; Noguchi CT; Diwan BA; Mohandas N; Cheung AT
    Blood; 2004 Nov; 104(10):3378-85. PubMed ID: 15271798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheological studies of erythrocyte-endothelial cell interactions in sickle cell disease.
    Barabino GA; McIntire LV; Eskin SG; Sears DA; Udden M
    Prog Clin Biol Res; 1987; 240():113-27. PubMed ID: 3615482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sickle erythrocyte adherence to large vessel and microvascular endothelium under physiologic flow is qualitatively different.
    Brittain HA; Eckman JR; Wick TM
    J Lab Clin Med; 1992 Oct; 120(4):538-45. PubMed ID: 1402330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
    Liles DK; Shah NR; Scullin B; Gordeuk VR; Smith WR; Kanter J; Achebe MM; Boccia R; Crary SE; Kraft WK; Archer N; Cataldo V; Hardesty BM; Idowu M; Desai PC; Ikeda A; Puthenveetil G; Hassell KL; Sarnaik S; Kutlar A
    Br J Haematol; 2021 Nov; 195(4):e150-e153. PubMed ID: 34611900
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.
    Gutsaeva DR; Parkerson JB; Yerigenahally SD; Kurz JC; Schaub RG; Ikuta T; Head CA
    Blood; 2011 Jan; 117(2):727-35. PubMed ID: 20926770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.
    Ataga KI; Moore CG; Hillery CA; Jones S; Whinna HC; Strayhorn D; Sohier C; Hinderliter A; Parise LV; Orringer EP
    Haematologica; 2008 Jan; 93(1):20-6. PubMed ID: 18166781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and rheological factors contributing to sickle cell microvascular occlusion.
    Kurantsin-Mills J; Lessin LS
    Blood Cells; 1986; 12(1):249-70. PubMed ID: 3790735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors.
    Telen MJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):341-54. PubMed ID: 24589270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment.
    Bachir D; Maurel A; Beuzard Y; Razavian M; Kraiem A; Portos JL; Galacteros F
    Microvasc Res; 1993 Nov; 46(3):359-73. PubMed ID: 8121319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombogenesis in sickle cell disease.
    Tomer A; Harker LA; Kasey S; Eckman JR
    J Lab Clin Med; 2001 Jun; 137(6):398-407. PubMed ID: 11385360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.
    Alshaiban A; Muralidharan-Chari V; Nepo A; Mousa SA
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):230-8. PubMed ID: 25601897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.